Pharmacokinetics-based comprehensive strategy to identify multiple effective components in Huangqi decoction against liver fibrosis
- PMID: 33647776
- DOI: 10.1016/j.phymed.2021.153513
Pharmacokinetics-based comprehensive strategy to identify multiple effective components in Huangqi decoction against liver fibrosis
Abstract
Background: Huangqi decoction (HQD) has been used to treat chronic liver diseases since the 11th century, but the effective components in HQD against liver fibrosis have not been definitively clarified.
Purpose: To investigate and identify multiple effective components in HQD against liver fibrosis using a pharmacokinetics-based comprehensive strategy.
Methods: The absorbed representative components in HQD and their metabolites were detected in human plasma and urine using high-resolution mass spectrometry combined with a database-directed method, and then pharmacokinetics in multiple HQD components in human plasma was analyzed by ultra-performance liquid chromatography coupled with triple-quadruple mass spectrometry. Furthermore, the anti-fibrotic effect of potential effective HQD components was studied in LX-2 cells and that of a multi-component combination of HQD (MCHD) was verified in a mouse CCl4-induced hepatic fibrosis model.
Results: Twenty-four prototype components in HQD and 17 metabolites were identified in humans, and the pharmacokinetic characteristics of 14 components were elucidated. Among these components, astragaloside IV, cycloastragenol, glycyrrhizic acid, glycyrrhetinic acid, liquiritigenin, and isoliquiritigenin downregulated the mRNA expression of α-SMA; cycloastragenol, calycosin-7-O-β-D-glucoside, formononetin, glycyrrhetinic acid, liquiritin, and isoliquiritin downregulated the mRNA expression of Col I; and calycosin, liquiritigenin, isoliquiritigenin, cycloastragenol, and glycyrrhetinic accelerated the apoptosis of LX-2 cells. MCHD reduced serum aminotransferase activity and hepatic collagen fibril deposition in mice with CCl4-induced hepatic fibrosis.
Conclusion: Using the pharmacokinetics-based comprehensive strategy, we revealed that multiple effective HQD components act together against liver fibrosis.
Keywords: Anti-liver fibrosis; Effective component; Huangqi decoction; Pharmacokinetics; Traditional Chinese medicine formula; Translational study.
Copyright © 2021. Published by Elsevier GmbH.
Similar articles
-
Simultaneous quantification of multiple components in rat plasma by UPLC-MS/MS and pharmacokinetic study after oral administration of Huangqi decoction.Biomed Chromatogr. 2018 May;32(5):e4178. doi: 10.1002/bmc.4178. Epub 2018 Jan 18. Biomed Chromatogr. 2018. PMID: 29243282
-
Protective effect of herbal medicine Huangqi decoction against chronic cholestatic liver injury by inhibiting bile acid-stimulated inflammation in DDC-induced mice.Phytomedicine. 2019 Sep;62:152948. doi: 10.1016/j.phymed.2019.152948. Epub 2019 May 5. Phytomedicine. 2019. PMID: 31129431
-
Huangqi decoction alleviates dimethylnitrosamine-induced liver fibrosis: An analysis of bile acids metabolic mechanism.J Ethnopharmacol. 2016 Aug 2;189:148-56. doi: 10.1016/j.jep.2016.05.040. Epub 2016 May 16. J Ethnopharmacol. 2016. PMID: 27196295
-
Advances in anti hepatic fibrotic therapy with Traditional Chinese Medicine herbal formula.J Ethnopharmacol. 2020 Apr 6;251:112442. doi: 10.1016/j.jep.2019.112442. Epub 2019 Dec 28. J Ethnopharmacol. 2020. PMID: 31891799 Review.
-
Promising traditional Chinese medicine for the treatment of cholestatic liver disease process (cholestasis, hepatitis, liver fibrosis, liver cirrhosis).J Ethnopharmacol. 2022 Oct 28;297:115550. doi: 10.1016/j.jep.2022.115550. Epub 2022 Jul 19. J Ethnopharmacol. 2022. PMID: 35863612 Review.
Cited by
-
Liver cirrhosis: current status and treatment options using western or traditional Chinese medicine.Front Pharmacol. 2024 Jul 16;15:1381476. doi: 10.3389/fphar.2024.1381476. eCollection 2024. Front Pharmacol. 2024. PMID: 39081955 Free PMC article. Review.
-
Astragali radix (Huangqi): a time-honored nourishing herbal medicine.Chin Med. 2024 Aug 30;19(1):119. doi: 10.1186/s13020-024-00977-z. Chin Med. 2024. PMID: 39215362 Free PMC article. Review.
-
Research Progress on the Ability of Astragaloside IV to Protect the Brain Against Ischemia-Reperfusion Injury.Front Neurosci. 2021 Nov 16;15:755902. doi: 10.3389/fnins.2021.755902. eCollection 2021. Front Neurosci. 2021. PMID: 34867166 Free PMC article. Review.
-
Research state of the herbal medicine Huangqi (Radix Astragali): A global and bibliometric study.Medicine (Baltimore). 2024 Feb 23;103(8):e37277. doi: 10.1097/MD.0000000000037277. Medicine (Baltimore). 2024. PMID: 38394541 Free PMC article.
-
Hepatoprotective Efficacy and Interventional Mechanism of Qijia Rougan Decoction in Liver Fibrosis.Front Pharmacol. 2022 Jul 1;13:911250. doi: 10.3389/fphar.2022.911250. eCollection 2022. Front Pharmacol. 2022. PMID: 35846987 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical